Focused On-demand Library for tRNA (cytidine(32)/guanosine(34)-2'-O)-methyltransferase

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9UET6

UPID:

TRM7_HUMAN

Alternative names:

2'-O-ribose RNA methyltransferase TRM7 homolog; Protein ftsJ homolog 1

Alternative UPACC:

Q9UET6; B2RCJ0; O75670

Background:

The tRNA (cytidine(32)/guanosine(34)-2'-O)-methyltransferase, also known as 2'-O-ribose RNA methyltransferase TRM7 homolog or Protein ftsJ homolog 1, plays a crucial role in the methylation of the 2'-O-ribose of nucleotides in tRNA anticodon loops. This modification is essential for accurate cytoplasmic translation, impacting translation efficiency, neurogenesis, mitochondrial translation, energy generation, and lipid biosynthesis. The protein's interaction with THADA and WDR6 is necessary for its function.

Therapeutic significance:

Given its involvement in Intellectual developmental disorder, X-linked 9, understanding the role of tRNA (cytidine(32)/guanosine(34)-2'-O)-methyltransferase could open doors to potential therapeutic strategies for treating intellectual developmental disorders and enhancing neurogenesis.